
Opinion|Videos|May 15, 2024
In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs
Selina McGee, OD, FAAO, evaluates the cost and efficacy of in-office procedures like microblepharoexfoliation, the potential clinical and economic costs associated with delaying access to the FDA-approved treatment through prior authorization or mandating prior use of traditional over-the-counter therapies like tea tree oil and lid wipes, and considers impact on patient adherence.
Advertisement
Episodes in this series

Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Top 5 stories from Formulary Watch in 2025
2
Jascayd gets second FDA approval, this time for progressive pulmonary fibrosis
3
What NCCN’s next CMO sees ahead for cancer guidelines, access and innovation
4
Top 5 articles about drug and healthcare costs in 2025
5




















































